Kymera Therapeutics, Inc. (KYMR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$117.39+0.09%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KYMR
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 105.0 | 39.2 | 47.1 | 78.6 | 46.8 | 72.8 | 34.0 |
| Cost of Revenues | 105.0 | 39.2 | 47.1 | 78.6 | 46.8 | — | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 375.6 | 316.6 | 240.2 | 189.1 | 164.2 | 137.0 | 62.1 |
| Operating Income | (350.2) | (349.4) | (261.6) | (165.5) | (161.3) | (100.5) | (46.3) |
| Earnings from Continuing Operations | |||||||
| Asset Writedown | — | — | 4.9 | 0.0 | 0.0 | — | — |
| EBT, Incl. Unusual Items | — | (311.4) | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||
| Net Income | 323.1 | (311.4) | (223.9) | 147.0 | 154.8 | 100.2 | (45.6) |
| Per Share | |||||||
| Basic EPS | 3.29 | (3.69) | (2.98) | (2.52) | (2.87) | (2.09) | (3.15) |
| Diluted EPS | 3.29 | (3.69) | (2.98) | (2.52) | (2.87) | (2.09) | (3.15) |
| Revenue per Share | 1.07 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 98.2 | 84.5 | 75.0 | 58.4 | 53.9 | 48.0 | 17.3 |
| Diluted Weighted Avg Shares | 98.2 | 84.5 | 75.0 | 58.4 | 53.9 | 48.0 | 17.3 |
| Supplemental | |||||||
| EBITDA | — | (341.1) | (254.3) | (162.0) | (158.3) | (98.1) | (44.5) |
| EBIT | (350.2) | (349.4) | (261.6) | (165.5) | (161.3) | (100.5) | (46.3) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.